• Annals of Clinical Neurophysiology
• /
• v.10 no.1
• /
• pp.13-24
• /
• 2008

Functional neuroimaging, especially positron emission tomography (PET) and functional magnetic resonance imaging (MRI), is the main tool that allows the unveiling of the neurovascular events during a migraine attack. In migraine with aura, functional neuroimaging has contributed greatly to the understanding of the fundamental pathophysiology of the visual aura, whereas in migraine without aura, the PET findings of brainstem activation suggest a pivotal role of brainstem in the generation of migraine headache. In addition, voxel-based morphometry (VBM) method has provided an insight into the morphometric changes of the brain, which might be considered as a consequence of repeated migraine attacks. In this article, I will briefly discuss the main neuroimaging findings pertaining to the pathophysiology of migraine.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.8 no.1
• /
• pp.25-32
• /
• 2022

Malignant melanoma has an aggressive nature and high metastatic potential that result in one of the highest cancer mortality rates. Over the past three decades, primary and metastatic melanoma incidence has rapidly increased. The recent advances in diagnostic technology have shown promise, but there is still an enormous need for specific detection methods to diagnose malignant melanoma. Positron emission tomography can visualize a particular biomarker of malignant melanoma and promise a noninvasive image of micrometastases. However, the development of PET radiopharmaceuticals remains necessary for diagnosing malignant melanoma by using positron emission tomography. In this review, the history and a general overview of PET radionuclide labeled benzamide derivatives, including their radiosynthesis, in vivo characterization, and evaluation, are provided as imaging agents for malignant melanoma.

• Journal of Radiopharmaceuticals and Molecular Probes
• /
• v.7 no.2
• /
• pp.93-98
• /
• 2021

meta-iodobenzylguanidine is one of the norepinephrine analogs and reuptakes together with norepinephrine with norepinephrine transporter. The radioiodinated ligand, ¹²³I-meta-iodobenzylguanidine, is the most widely used for single photon emission computed tomography imaging to diagnose functional abnormalities and tumors of the sympathetic nervous system. In this study, we performed cellular uptake studies of ¹²³I-meta-iodobenzylguanidine in positive- and negative-norepinephrine transporter cells in vitro to verify the uptake activity for norepinephrine transporter. After ¹²³I-meta-iodobenzylguanidine was injected via a tail vein into normal mice, Single photon emission computed tomography/computed tomography images were acquired at 1 h, 4 h, and 24 h post-injection, and quantified the distribution in each organ including the adrenal medulla as a norepinephrine transporter expressing organ. In vitro cell study showed that ¹²³I-meta-iodobenzylguanidine specifically uptaked via norepinephrine transporter, and significant uptake of ¹²³I-meta-iodobenzylguanidine in the adrenal medulla in vivo single photon emission computed tomography images. These results demonstrated that single photon emission computed tomography imaging with ¹²³I-meta-iodobenzylguanidine were able to quantify the biodistribution in vivo in the adrenal medulla in normal mice.

• Korean Journal of Radiology
• /
• v.1 no.1
• /
• pp.51-55
• /
• 2000

Objective: To determine the accuracy of CT and positron emission tomography (PET) in the diagnosis of recurrent uterine cervical cancer. Materials and Methods: Imaging findings of CT and PET in 36 patients (mean age, 53 years) in whom recurrent uterine cervical cancer was suspected were analyzed retrospectively. Between October 1997 and May 1998, they had undergone surgery and/or radiation therapy. Tumor recurrence was confirmed by pathologic examination or follow-up studies. Results: In detecting recurrent uterine cervical cancer, the sensitivity, specificity, and accuracy of CT were 77.8%, 83.3%, and 80.5%, respectively, while for PET, the corresponding figures were 100%, 94.4%, and 97.2%. The Chi-square test revealed no significant difference in specificity (p = .2888), but significant differences in sensitivity (p = .0339) and accuracy (p = .0244). Conclusion: PET proved to be a reliable screening method for detecting recurrent uterine cervical cancer, but to determine the anatomical localization of recurrent tumors, and thus decide an adequate treatment plan, CT was eventually needed.

• Radiation Oncology Journal
• /
• v.29 no.3
• /
• pp.214-217
• /
• 2011

To avoid improper tumor volume contouring in radiation therapy (RT) and other invasive procedures, we report a case of uterine adenomyosis showing increased $^{18}F$-fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET)/computed tomography (CT) mimicking malignant tumor in a 44-year-old woman during concurrent chemoradiation therapy (CCRT) for uterine cervical cancer. The adenomyosis was not associated with her menstrual cycle or with normal endometrium uptake, and it resolved one month after completion of RT. This case indicates that uterine adenomyosis in a premenopausal woman may show false positive uptake of $^{18}FDG$-PET/CT associated with CCRT.

• Imaging Science in Dentistry
• /
• v.44 no.4
• /
• pp.325-332
• /
• 2014

A combination of positron emission tomography (PET) with $^{18}F$-labeled fluoro-2-deoxyglucose ($^{18}F$-FDG) and computed tomography ($^{18}F$-FDG-PET/CT) has increasingly become a widely used imaging modality for the diagnosis and management of head and neck cancer. On the basis of both recent literature and our professional experience, we present a set of principles with pictorial illustrations and clinical applications of FDG-PET/CT in the evaluation and management planning of squamous cell carcinoma of the oral cavity and oropharynx. We feel that this paper will be of interest and will aid the learning of oral and maxillofacial radiology trainees and practitioners.

• Nuclear Medicine and Molecular Imaging
• /
• v.43 no.5
• /
• pp.505-507
• /
• 2009

A 60-year-old woman, who had non-small-cell lung cancer (NSCLC) in left lower lobe underwent brain F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for evaluation of cerebral metastasis. On follow-up FDG-PET/CT, only hypometaolic lesion was detected and progressed in right frontal lobe at 6 months and 10 months, later. Hypermetabolic metastasis was not detected even at last scan time of FDG-PET/CT. Brain MRI showed brain metastasis in right frontal lobe. As might be expected, the physician should take cerebral metastasis into consideration even though there is only hypometabolic change on subsequent FDG-PET/CT in patients with NSCLC.

• Imaging Science in Dentistry
• /
• v.36 no.2
• /
• pp.111-116
• /
• 2006

PET/CT is a new imaging technology that combines high-quality Positron Emission Tomography (PET) and Computed Tomography (CT). This imaging provides simultaneous anatomical and metabolic information. Therefore PET/CT is useful diagnostic modality for early detection of malignant tumor, accurate staging, decision on therapeutic plan, monitoring response to therapy and rapid detection of recurrence. We report oral and maxillofacial cancers diagnosed by using PET/CT and the usefulness of PET/CT in the evaluation of postoperative recurrence.

• Journal of the Optical Society of Korea
• /
• v.14 no.1
• /
• pp.49-54
• /
• 2010

In this study, the use of a continuous-wave (CW) supercontinuum (SC) seeded by an erbium-doped fiber's amplified spontaneous emission (ASE) for optical-coherence tomography imaging is experimentally demonstrated. It was shown, by taking an in-depth image of a human tooth sample, that due to the smooth, flat spectrum and long-term stability of the proposed CW SC, it can be readily applied to the spectral-domain optical-coherence tomography system. The relative-intensity noise level and spectral bandwidth of the CW SC are also experimentally analyzed as a function of the ASE beam power.

• Journal of Cardiovascular Imaging
• /
• v.31 no.3
• /
• pp.150-151
• /
• 2023